Huge gains from our trading list yet again! Go KPTI! Today's big winner!Karyopharm price target raised to $43 from $40 at H.C. Wainwright - $KPTIH.C. Wainwright analyst Edward White raised the firm's price target on Karyopharm to $43 from $40 and reiterated a Buy rating on the shares. The price target raise followed positive results from Karyopharm's BOSTON study for Xpovio in Multiple Myeloma, with the trial's primary endpoint of a statistically significant increase in progression free survival reached. White said he now sees an "increased probability of success estimate for Xpovio in combination treatment for multiple myeloma" and he has increased his Xpovio sales estimates.Cowen starts Amarin at Outperform on market 'meaningfully discounting' VascepaCowen analyst Ken Cacciatore initiated coverage of Amarin with an Outperform rating and $23 price target. The shares closed Friday at $14.67. Vascepa's supplemental new drug application was approved in December 2019 for cardiovascular risk reduction in patients with high triglycerides on top of statins, roughly quadrupling the number of patients who could benefit from it, Cacciatore tells investors in a research note. The only near-term risk for Amarin is the ongoing generic litigation, but legal consultants believe that Vascepa's patents are defensible, adds the analyst. Cacciatore believes the shares around $15 assume only a 15% penetration of the target market, or $3B in U.S. Vascepa revenues by 2028. "We clearly believe the current trading level is meaningfully discounting the potential of this product," says the analyst. His $23 target assumes 25% penetration into the recently expanded patient population in the U.S. by 2028, or roughly $5B in Vascepa sales that year. Further, moving past the patent litigation will be the "final gating item before serious acquisition conversations can begin," argues Cacciatore.Currently high on our list or recent big winners > $SGMO $TDOC $IMMU $TGTX $COLL $KPTI, Karyopharm Therapeutics Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page